Company search
Overview
Performance
Portfolio
ESG
Dividends
Charges
Gearing
Research
Announcements
Management
Documents
Invest
Data as at: 17/04/2024
In
Objective
To achieve long-term capital growth by investing in biotechnology and other life sciences companies.
AIC sector
Management group
Schroder Investment Management
Company website
Launch date
06/05/1994
August
Domicile
United Kingdom
Fund manager
Ailsa Craig, Marek Poszepczynski
Dividend frequency
Semi-Annually
Wind-up provisions
The Association Articles of the company provide for Directors to put forward a proposal for the continuation of the company at the AGM at two-yearly intervals. The upcoming continuation vote is scheduled for the December 2025 AGM.
| Market Cap (m) | Total assets (m) | Price (last close) | NAV | Discount / premium (%) | Gearing (%) | Dividend yield (%) | Dividend dates | Ongoing charge (%) |
|---|---|---|---|---|---|---|---|---|
| 234.91 | 288.29 | 621.00 | 687.47 | -9.67 | 10 | 4.54 | Jul, Dec | 1.4 (31/08/2023) |
Scroll
Dividends
Dividends declared in last 12 months
| Ex-Dividend date | Payment date | Dividend amount | Special dividend | Financial year |
|---|---|---|---|---|
| 21/12/2023 | 26/01/2024 | 13.900 | No | 2024 |
| 27/07/2023 | 25/08/2023 | 14.200 | No | 2023 |
Scroll
Performance (%)
| Return type | 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|---|
| International Biotechnology | Share price total return | -3.4 | -4.0 | 21.5 | 229.5 |
| Biotechnology & Healthcare AIC sector | Share price total return | -1.1 | -22.2 | 1.6 | 132.9 |
Scroll
Share structure
Number of shares
37,827,787
3,556,030
Traded volumes (number of shares)
| Yesterday | 1 month | 1 year | 5 years | |
|---|---|---|---|---|
| Total | 47,156 | 1,221,922 | 12,874,844 | 82,781,628 |
| Average | N/A | 60,432 | 50,828 | 65,690 |
Scroll
Traded values (m)
| Yesterday | 1 month | 1 year | 5 years | |
|---|---|---|---|---|
| Total | 0.29 | 7.86 | 82.19 | 569.14 |
| Average | N/A | 0.39 | 0.32 | 0.45 |
Scroll
Trading details
Top holdings
Data as at : 31/03/2024
| Investment | % of total assets |
|---|---|
| Amgen Inc | 5.6 |
| Cytokinetics Inc | 5.1 |
| Sv Fund Vi Investment | 4.8 |
| Gilead Sciences Inc | 4.4 |
| Vera Therapeutics Inc Class A | 4.3 |
| Biomarin Pharmaceutical Inc | 4.3 |
| Incyte Corp | 3.7 |
| Supernus Pharmaceuticals Inc | 3.5 |
| Alnylam Pharmaceuticals Inc | 3.4 |
| Scb Sholo211123b 20-Mar-2024 6.46% 22-Apr-2024 | -10.0 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.
